Eosinophilia and elevated serum levels of eosinophil major basic protein and Charcot-Leyden crystal protein (lysophospholipase) after treatment of patients with Bancroft's filariasis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001798:Blood Proteins; D002648:Child; D003460:Crystallization; D004049:Diethylcarbamazine / Q000627:therapeutic use; D047091:Eosinophil Granule Proteins; D004802:Eosinophilia / Q000097:blood*; D005368:Filariasis / Q000188:drug therapy / Q000469:parasitology; D006023:Glycoproteins; D006801:Humans; D008245:Lysophospholipase / Q000097:blood*; D008875:Middle Aged; D010740:Phospholipases / Q000097:blood*; D012044:Regression Analysis; D012260:Ribonucleases; D014958:Wuchereria bancrofti
D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D006023:Glycoproteins; D010740:Phospholipases; D012260:Ribonucleases; D008245:Lysophospholipase; C011711:lysolecithin acylhydrolase; D004049:Diethylcarbamazine